Introduction
Pharmacological suppression of the donor-derived alloreactive immune response has played a central role in reducing the morbidity and mortality of graft-versus-host disease (GVHD), which still remains the major cause of toxicity after allogeneic stem cell transplantation (SCT). At the same time, it has become clear that the intensity of posttransplant immunosuppression is one of the most important determinants of relapse risk through its impact on the potency of an immunologically mediated graft-versusleukaemia (GVL) effect. This is particularly relevant in patients undergoing allogeneic SCT using a reducedintensity conditioning (RIC) regimen, where a GVL effect represents the dominant anti-leukaemic mechanism. Accordingly, there is now a developing interest in tailoring the intensity and duration of post-transplant immunosuppression according to the perceived risk of GVHD and disease relapse in an individual patient.
In the past few years considerable refinement has occurred in the pharmacologically mediated immunosuppressive strategies utilized in recipients of solid organ transplants. This has occurred through the use of more precise methods of monitoring established agents, principally cyclosporin (CsA), which have been shown to reduce the risk of graft rejection in the setting of both kidney and liver transplantation. This experience suggests that there may be scope for translating the advances that have been made in the field of solid organ transplantation to recipients of allogeneic haematopoietic stem cells. This review will focus on the basis for current immunosuppressive strategies in patients undergoing allogeneic haematopoietic SCT and discuss whether there is room for improving both the monitoring and the delivery of pharmacologically mediated immunosuppression in this population of patients.
The role of cyclosporin and other immunosuppressants in graft-versus-host disease prophylaxis
Cyclosporin has become the most widely used agent for the prevention of GVHD in patients undergoing allogeneic SCT after initial studies by Powles 1 demonstrated that its administration, in conjunction with methotrexate, resulted in a substantial reduction in the incidence and severity of acute GVHD and had a positive impact on survival. This pioneering work was subsequently confirmed by randomized controlled trials from the Seattle group. 2 In recent years a number of newer immunosuppressants have entered clinical practice and have been compared to the standard CsA plus methotrexate regimen (Table 1) [3] [4] [5] [6] . The maximum experience has been gained with tacrolimus, a calcineurin inhibitor that is chemically unrelated to CsA. Two large randomized phase III trials of tacrolimus plus methotrexate versus CsA plus methotrexate have been published, both of which showed a significantly reduced incidence of acute GVHD in patients receiving tacrolimus. [3] [4] [5] However, there was no difference in the incidence of chronic GVHD in either study and in the study involving patients undergoing a sibling allograft, overall survival was in fact worse in the tacrolimus plus methotrexate arm. 3 As yet, only one small randomized phase III trial of mycophenolate mofetil as GVHD prophylaxis has been published. 6 Mycophenolate used in combination with CsA resulted in similar rates of GVHD and a comparable overall survival to cyclosporin plus methotrexate but was better tolerated in terms of faster engraftment and less mucositis. Encouraging results have also been reported with sirolimus, a macrocyclic lactone immunosuppressant that is structurally similar to tacrolimus. 7, 8 Despite these developments, the combination of CsA and methotrexate remains the standard approach by GVHD prophylaxis in the majority of transplant centres. However, there is still uncertainty as to the optimal schedule for dosage, administration and monitoring of CsA. 9 A survey of 87 centres by the European Group for Blood and Marrow Transplantation 9 showed inconsistency in both timing of CsA infusion and variations in the range of dose from 1 to 20 mg/kg/day. Reference ranges also varied widely between 100 and 1000 mg/l. There was also a lack of standardization in assay techniques with both whole blood and serum being used for measurement and a number of different assay methods being employed. A recent survey of UK practice involving 19 transplant centres produced results similar to those described above revealing target concentrations for CsA ranging from 85 up to 800 mg/l.
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Although there is clearly uncertainty surrounding the optimal use of CsA in the setting of GVHD prophylaxis, accumulating data attests to the potential clinical benefits of close attention to CsA dosing schedules and monitoring. In an important study in which patients undergoing a sibling allograft were randomized to 1 or 5 mg/kg/day CsA, Bacigalupo demonstrated a significantly higher rate of acute and chronic GVHD in patients receiving 1 mg/kg CsA. This was offset by a decreased risk of relapse in patients receiving low-dose CsA, resulting in improved disease-free survival in this group of patients. 11, 12 Other groups have shown that close monitoring of CsA can produce benefits in terms of a reduced incidence of acute GVHD 13 while extended CsA administration has the capacity to reduce the risk of chronic GVHD. 14 More recently it has been demonstrated that posttransplant immunosuppression using CsA permits durable engraftment of allogeneic stem cells using a non-myeloablative regimen. 15 In the setting of allografts performed using a RIC regimen, where the dominant anti-tumour effect of the allograft is exerted by an immunologically mediated GVL effect, CsA is rapidly tapered post transplant. However, the optimal dosing schedule and duration of CsA administration in patients undergoing RIC allografts and the impact on relapse and GVHD are unknown, and requires urgent further study. This is particularly true in patients in whom T-cell depletion using alemtuzemab or anti-thymocyte globulin is used, where relapse is the most important cause of treatment failure and reduction in CsA dose intensity may represent an important, and largely unexplored, approach towards improving outcome. 16 Clearly therefore CsA plays a critical role in determining the outcome of allogeneic SCT using both myeloablative and RIC regimens and this has led to renewed interest in refining the current techniques available for monitoring both the blood level and the pharmacological activity of CsA after allogeneic SCT.
Pharmacology of CsA
Cyclosporin was first introduced into clinical practice in 1978 17 and has become the cornerstone of immunosuppression in the settings of solid organ (renal, hepatic and cardiac) and SCT. 18 Cyclosporin exerts its immunosuppressive effects through suppression of calcineurinmediated T-lymphocyte activation and accumulating evidence demonstrates that peak levels of CsA correlate best with the degree of calcineurin inhibition achieved. 19 Consequently, factors determining peak as well as trough levels of CsA may significantly impact on the degree of immunosuppression produced by patients receiving this agent post transplant. This is of particular importance given that CsA pharmacokinetics are highly variable, with factors such as transplant type, patient age and concurrent drug therapy all influencing blood concentrations of the drug. 20 Variable absorption of oral CsA is well documented, and can result in marked differences in bioavailability between patients. 21 In the SCT setting, absolute bioavailability of oral CsA may vary from 20 to 50%. 22 However, in the first few days post transplant, mucositis caused by the pre-transplant conditioning regimen impairs absorption of CsA from the upper gastrointestinal tract. 23 In addition, Optimizing the use of cyclosporin in allogeneic SCT N Duncan and C Craddock oral mucositis can make it difficult for the patient to tolerate an oral formulation. Consequently, administration of the drug by the intravenous route until mucositis has resolved is standard practice in almost all transplant centres. Cyclosporin is extensively metabolized, with the liver being the main site of metabolism. Age and hepatic function can impact on CsA clearance 24 and drugs commonly used in the setting of SCT such as phenytoin, 25 itraconazole, 26 fluconazole 27 and macrolide antibiotics, 28, 29 can also influence the metabolism of CsA. For example, phenytoin can reduce CsA concentrations by 50%, 25 via induction of hepatic microsomal enzymes.
Given the marked interpatient variability in CsA pharmacokinetics and the importance of maintaining a balance between underdosing (and thus increasing the risk of GVHD or rejection) and overdosing (and thus increasing the risk of toxicity), blood-level monitoring has for many years been the standard practice for patients receiving CsA in the solid organ and SCT settings. 30 Trough-level monitoring was first introduced into clinical practice in the early 1980s 30 and despite its widespread usage over the subsequent two decades, there has remained a degree of uncertainty as to whether this approach is the most appropriate way of performing drug monitoring of CsA. In the setting of GVHD prophylaxis, a number of authors have demonstrated an inverse relation between trough CsA levels and incidence of GVHD. [31] [32] [33] [34] However, other authors have failed to demonstrate a significant relationship between trough concentrations and aGVHD [35] [36] [37] [38] and conflicting findings have also been reported when studying the association between CsA levels and the risk of nephrotoxicity. [37] [38] [39] Given that there appears to be a lack of a strong association between trough CsA concentrations and measures of both efficacy and toxicity in the SCT setting, it is instructive to focus on the solid organ transplantation literature, where the issue of how best to monitor CsA has generated significant interest in the past two decades.
Cyclosporin monitoring in the setting of solid organ transplantation
Early studies using oral CsA in solid organ transplantation suggested that trough concentrations correlated with clinical outcomes, both in terms of rejection and nephrotoxicity 40, 41 and also that the correlation with trough levels was better than with the maximum concentration (C max ). 18 Consequently, trough-level monitoring became the standard practice, 30 although concern remained that this technique was still an imperfect tool. This was illustrated by data showing that the rates of acute rejection and nephrotoxicity in patients with trough CsA concentrations within a defined therapeutic range remained 59 and 63%, respectively. 42 Subsequent work showed that trough CsA levels did not correlate with drug exposure as estimated by the area under the concentration time curve (AUC) 43 and others demonstrated that the correlation between trough levels and clinical outcomes was relatively poor 42, [44] [45] [46] [47] [48] [49] [50] in the settings of renal, liver and heart transplantation.
These concerns led to increased interest in developing alternative monitoring strategies for CsA and a number of studies demonstrated the benefit of AUC monitoring as a superior indicator of drug exposure and clinical events in the setting of renal transplantation. [51] [52] [53] However, full AUC monitoring is a time consuming and relatively impractical process, so efforts were made to simplify its determination. This led to the development of sparse-sampling algorithms, 54 ,55 which used two or three time points as surrogate markers for exposure to CsA and were found to correlate with AUC. The logical progression of this approach was to find a single time-point measure which correlated best with AUC and a number of studies showed that a sample taken 2 h after an oral dose of CsA (C 2 ) was the most accurate single marker of exposure with a correlation coefficient of r 2 40.80 across a variety of transplant populations. 46, 47, 56 In addition to demonstrating an association between C 2 and AUC, it was also noted that there was good correlation between C 2 and C max . 57 The emerging evidence that calcineurin inhibition correlated well with CsA levels, with maximal inhibition occurring during the period of highest CsA concentration, 19 provided a further pharmacodynamic argument for utilizing C 2 monitoring in the post-transplant setting.
A number of trials have employed C 2 monitoring in solid organ transplantation [58] [59] [60] and demonstrated superior outcomes in terms of rejection rates and acute toxicities compared to trough-level monitoring. This has led some to conclude that C 2 monitoring is now the optimal method of monitoring oral CsA in the setting of de novo renal and hepatic transplants. 61 Consequently, C 2 monitoring is being increasingly employed in the management of solid organ recipients with a recent survey of renal transplant centres finding that almost half the respondents were now measuring C 2 concentrations. 62 Improving strategies for immunosuppression after allogeneic haematopoietic stem cell transplantation
In the past 5 years, the monitoring of oral CsA in the setting of solid organ transplantation has undergone significant change, based on concerns regarding the validity of the traditional system of trough-level monitoring. Given the marked interpatient variability in the absorption of oral CsA and the findings that the peak CsA concentration correlates well with maximum inhibition of calcineurin, 19 the move towards C 2 monitoring seems logical from both pharmacokinetic and pharmacodynamic perspectives. In the SCT setting, where it is clear that our current practice of trough-level monitoring still results in unacceptably high levels of aGVHD, there is scope to explore the potential of monitoring the drug (both i.v. and oral) via alternative measures of exposure or activity. For example, it will be important to determine whether the AUC or peak level, rather than the trough level, provides a more accurate measure of post-transplant immunosuppression. Importantly, whatever pharmacokinetic marker is employed, there remains the concern that this may not accurately reflect the functional activity of the drug, and this has led a number of groups to investigate the use of calcineurin activity as a marker of immunosuppression after allogeneic SCT. 63, 64 Significantly, it has been reported that the risk of
Optimizing the use of cyclosporin in allogeneic SCT N Duncan and C Craddock developing of acute GVHD correlates with the degree of calcineurin inhibition in the mononuclear cells of patients in the first 2 months post transplant and this potentially important observation requires validation in a larger cohort of patients. 64 There is also emerging evidence that there is significant inter-patient variation in the degree of calcineurin inhibition produced by a consistent dose of CsA, emphasizing the importance of correlating biological measures of calcineurin inhibition with clinical outcome. 65 
Conclusions and future directions
In conclusion, it is clear that CsA plays a central, and sometimes underestimated, role in optimizing outcome after allogeneic SCT. This is particularly the case in the setting of RIC allografts, where CsA's impact on the potency of the alloreactive response plays a critical role in modulating the GVL effect post allograft. However, despite its importance in determining outcome, there is little consensus concerning how CsA is administered or monitored. In light of the emerging evidence from solid organ transplants that peak levels of CsA may determine clinical alloreactivity, a reassessment of monitoring strategies with respect to GVHD and disease relapse is now important in the setting of both myeloablative and RIC allografts For example, we would propose that studies are undertaken to address the issue of whether peak-level monitoring may be superior to trough-level monitoring in SCT patients receiving both i.v. and oral cyclosporin. In addition, in light of the fact that relapse remains the major cause of treatment failure after RIC allografts, randomized controlled studies examining both the dose intensity and duration of CsA administration after allogeneic SCT are now indicated. These studies are of particular importance given the current limitations in intensifying the preparative regimen without compromising the ability of RIC allograft protocols to extend the age at which allogeneic SCT can be safely performed. It is therefore clearly time to re-evaluate the optimal use of one of the oldest drugs in the transplant armamentarium.
Cyclosporin dose intensity is an important and readily manipulable determinant of the incidence of GVHD post allogeneic SCT and plays a particularly important role in determining outcome after RIC allografts. Dose intensity of cyclosporin should be adjusted according to the perceived risk of disease relapse and cGVHD. Trough levels of cyclosporin correlate poorly with the degree of immunosuppression and outcome in solid organ transplantation. In the setting of solid organ transplantation there is increased interest in the use of peak-level monitoring of oral cyclosporin. Optimal strategies for monitoring cyclosporin dose intensity in the setting of stem cell transplantation remain to be defined and require randomized studies in the setting of both myeloablative and RIC allografts.
